NCT05979155 is a Phase 1 clinical trial of NWY001 in Advanced Solid Tumor, sponsored by Chipscreen Biosciences, Ltd..

Who is sponsoring NCT05979155?

NCT05979155 is sponsored by Chipscreen Biosciences, Ltd..

What drugs are being tested in NCT05979155?

Interventions in NCT05979155: NWY001, NWY001.

What condition does NCT05979155 study?

NCT05979155 studies Advanced Solid Tumor.

Is NCT05979155 still recruiting?

NCT05979155 is currently recruiting now. Last updated 15 July 2024.

Last reviewed 2024-07-15 · How we verify

NCT05979155

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Multicenter, Non-randomized, Open-label, Multiple-Dose Phase I Study of NWY001, in Subjects With Advanced Solid Tumors

Recruiting now Phase 1 Last updated 15 July 2024

What this trial tests

Phase 1 trial testing NWY001 in Advanced Solid Tumor in 196 participants. Currently enrolling.

Timeline

5 January 2024

Primary endpoint
1 January 2026

1 May 2028

Quick facts

Lead sponsor	Chipscreen Biosciences, Ltd.
Phase	Phase 1
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	non randomized
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	196
Start date	5 January 2024
Primary completion	1 January 2026
Estimated completion	1 May 2028
Sites	1 location across China

Drugs / interventions tested

NWY001 — full drug profile →
NWY001 — full drug profile →

Conditions studied

Advanced Solid Tumor — all drugs for Advanced Solid Tumor →

Sponsor

Chipscreen Biosciences, Ltd. — full company profile →

Who can join

Adults 18 to 75, any sex, with Advanced Solid Tumor. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Dose-limiting toxicity (DLT)
Time frame: Up to 21 days
Number of patients experienced any dose limited toxicity
Incidence of adverse events (AEs)
Time frame: Until 30 days after the last dose of the study drug
Number of patients experienced AEs

Sponsor's own description

This is a Phase 1, single-arm, open-label, dose-escalation study in patients with advanced solid tumors including 2 parts: Part 1: Dose-Escalation Part Part 2: Dose-Expansion Part

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Advanced Solid Tumor

Currently open trials in the same condition.

NCT07300943 — Study in Advanced Solid Tumor Patients · Phase 1, PHASE2 · recruiting
NCT07304128 — A Study of PLB-002 in Advanced Solid Tumors · Phase 1 · recruiting
NCT07213830 — A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Anti-tumour Activity · Phase 1, PHASE2 · recruiting
NCT07226349 — A Study of BG-75098 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors · Phase 1 · recruiting
NCT07222267 — An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Soli · Phase 1 · recruiting

Other Chipscreen Biosciences, Ltd. trials

Trials by the same sponsor.

NCT07511010 — Food Effect and Multiple-Dose Study of Chiglitazar/Metformin Extended-Release Tablets · Phase 1 · not yet recruiting
NCT07519265 — Bioequivalence Study of Chiglitazar/Metformin Extended-Release Tablets · NA · not yet recruiting
NCT07412015 — Pilot Bioequivalence Study of Chiglitazar/Metformin Extended-Release Tablets · NA · not yet recruiting
NCT07445295 — Chiauranib Plus PD-1 Inhibitor, Albumin-paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Ductal Adenoca · Phase 3 · not yet recruiting
NCT07129382 — A Study to Evaluate the Efficacy and Safety of CS32582 in Participants With Moderate to Severe Plaque Psoriasis · Phase 1, PHASE2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05979155 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Chipscreen Biosciences, Ltd.
Last refreshed: 15 July 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05979155.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing